NUFORMIX PLC

Report Publication Announcement • Nov 12, 2021

National Storage Mechanism | Additional information

RNS Number : 1492S

Nuformix PLC

12 November 2021

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Nuformix plc

("Nuformix" or the "Company")

NXP004 patent application filing

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that it has filed a new patent application in relation to NXP004.

This filing covers a new family of co-crystalline forms of an undisclosed marketed drug that is approved globally for the treatment of several cancers and that had global sales of over £1bn in 2020. This is the second patent application related to NXP004 that Nuformix has filed and it complements the previous patent application on NXP004 co-crystals, thus expanding the Company's intellectual property portfolio.

Anne Brindley, Chief Executive Officer, Nuformix, commented: "We are pleased to have filed this new patent application for NXP004. Data that we have generated on these new co-crystal forms in the past six months has shown improvements over the marketed form that justifies filing this new application. This application, if granted, will strengthen the patent estate for NXP004 and Nuformix's IP portfolio as a whole."

Enquiries:

Nuformix plc			via Walbrook
Dr Alastair Riddell, Non-Executive Chairman
Dr Anne Brindley, CEO
Allenby Capital Limited			+44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate Finance)
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)
Walbrook PR	nuformix@walbrookpr.com or +44 (0)20 7933 8780
Anna Dunphy / Phillip Marriage		Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFLDLTLLLIL